Systemic gene delivery to the central nervous system using Adeno-associated virus

Frontiers in Molecular Neuroscience

Volumn 7, Issue JUNE, 2014, Pages

  Bourdenx, Mathieu ^a,b   Dutheil, Nathalie ^a,b   Bezard, Erwan ^a,b   Dehay, Benjamin ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

AAV; Gene therapy; Neurodegenerative diseases; Neurological disorders; Systemic delivery

Indexed keywords

MICRORNA; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; BLOOD BRAIN BARRIER; BRAIN SURGERY; BRAIN TRANSDUCTION; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; DNA SHUFFLING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSDUCTION; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; REVIEW; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME;

EID: 84901832947     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00050     Document Type: Review

References (81)

1. Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., Kay, M. A., et al. (2006). The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.J. Virol. 80, 9831-9836. doi: 10.1128/JVI.00878-06
2. Bartus, R. T., Baumann, T. L., Brown, L., Kruegel, B. R., Ostrove, J. M., Herzog, C. D., et al. (2013). Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol. Ag. 34, 35-61. doi: 10.1016/j.neurobiolaging.2012.07.018
3. Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G. P., Van Vliet, K., et al. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice.J. Clin. Invest. 121, 2427-2435. doi: 10.1172/JCI57367
4. Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., et al. (2011). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971-1980. doi: 10.1038/mt.2011.157
5. Bevan, A. K., Hutchinson, K. R., Foust, K. D., Braun, L., McGovern, V. L., Schmelzer, L., et al. (2010). Early heart failure in the SMN 7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895-3905. doi: 10.1093/hmg/ddq300
6. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712. doi: 10.1089/hum.2009.182
7. Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., et al. (2011). Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol. 18, 1586-1588. doi: 10.1128/CVI.05107-11
8. Chen, Y. H., Chang, M., and Davidson, B. L. (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15, 1215-1218. doi: 10.1038/nm.2025
9. Colangelo, A. M., Alberghinaa, L., and Michele Papa, C. (2014). Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci. Lett. 565, 59-64. doi: 10.1016/j.neulet.2014.01.014
10. Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., et al. (2013). In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra76. doi: 10.1126/scitranslmed.3005708
11. Dalkara, D., Byrne, L. C., Lee, T., Hoffmann, N. V., Schaffer, D. V., Flannery, J. G., et al. (2011). Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 19, 176-181. doi: 10.1038/gt.2011.163
12. Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., et al. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A.97, 3428-3432. doi: 10.1073/pnas.97.7.3428
13. Dayton, R. D., Wang, D. B., and Klein, R. L. (2012). The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin. Biol. Ther. 12, 757-766. doi: 10.1517/14712598.2012.681463
14. Decressac, M., Mattsson, B., Lundblad, M., Weikop, P., and Björklund, A. (2012). Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45, 939-953. doi: 10.1016/j.nbd.2011.12.013
15. Dehay, B., Dalkara, D., Dovero, S., Li, Q., and Bezard, E. (2012). Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Sci. Rep.2, 253. doi: 10.1038/srep00253
16. Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A. M., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196. doi: 10.1038/mt.2009.71
17. Engeln, M., Fasano, S., Ahmed, S. H., Cador, M., Baekelandt, V., Bezard, E., et al. (2013). Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann. Neurol. 74, 140-144. doi: 10.1002/ana.23881
18. Federici, T., Taub, J. S., Baum, G. R., Gray, S. J., Grieger, J. C., Matthews, K. A., et al. (2012). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19, 852-859. doi: 10.1038/gt.2011.130
19. Ferrari, F. K., Samulski, T., Shenk, T., and Samulski, R. J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.J. Virol. 70, 3227-3234.
20. Ferrari, F. K., Xiao, X., McCarty, D., and Samulski, R. J. (1997). New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat. Med. 3, 1295-1297. doi: 10.1038/nm1197-1295
21. Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., and Kaspar, B. K. (2008). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65. doi: 10.1038/nbt.1515
22. Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274. doi: 10.1038/nbt.1610
23. Fu, H., Dirosario, J., Killedar, S., Zaraspe, K., and McCarty, D. M. (2011). Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19, 1025-1033. doi: 10.1038/mt.2011.34
24. Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues.J. Virol. 78, 6381-6388. doi: 10.1128/JVI.78.12.6381-6388.2004
25. Gray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., McCown, T. J., et al. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570-578. doi: 10.1038/mt.2009.292
26. Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., et al. (2011a). optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143-1153. doi: 10.1089/hum.2010.245
27. Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., and Samulski, R. J. (2011b). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069. doi: 10.1038/mt.2011.72
28. Gray, S. J., and Samulski, R. (2011). "Vector design and considerations for CNS applications, " inGene Vector Design and Application to Treat Nervous System Disorders, ed. J. Glorioso (Washington, DC: Society for Neuroscience), 1-9.
29. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745-2760. doi: 10.1089/hum.1998.9.18-2745
30. Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.J. Virol. 82, 5887-5911. doi: 10.1128/JVI.00254-08
31. Hermening, S., Kügler, S., Bähr, M., and Isenmann, S. (2006). Improved high-capacity adenoviral vectors for high-level neuron-restricted gene transfer to the CNS.J. Virol. Methods136, 30-37. doi: 10.1016/j.jviromet.2006.03.031
32. Hermonat, P. L., and Muzyczka, N., (1984). Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. U.S.A. 81, 6466-6470. doi: 10.1073/pnas.81.20.6466
33. Iida, A., Takino, N., Miyauchi, H., Shimazaki, K., and Muramatsu, S. (2013). Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. BioMed Res. Intl.2013, 1-8. doi: 10.1155/2013/974819
34. Iwata, N., Kobayashi, K., Sasaoka, T., Hidaka, H., and Nagatsu, T. (1992). Structure of the mouse tyrosine hydroxylase gene. Biochem. Biophys. Res. Commun. 182, 348-354. doi: 10.1016/S0006-291X(05)80151-2
35. Iwata, N., Sekiguchi, M., Hattori, Y., Takahashi, A., Asai, M., Ji, B., et al. (2013). Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep. 3, 1472. doi: 10.1038/srep01472
36. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., et al., (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet369, 2097-2105. doi: 10.1016/S0140-6736(07)60982-9
37. Kaspar, B. K. (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science301, 839-842. doi: 10.1126/science.1086137
38. Klein, R. L., Dayton, R. D., Tatom, J. B., Diaczynsky, C. G., and Salvatore, M. F. (2008). Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. Eur. J. Neurosci. 27, 1615-1625. doi: 10.1111/j.1460-9568.2008.06161.x
39. Korecka, J., Schouten, M., Eggers, R., Ulusoy, A., Bossers, K., and Verhaagen, J. (2011). "Comparison of AAV serotypes for gene delivery to dopaminergic neurons in the Substantia Nigra, " inViral Gene Therapy, ed. K. Xu (Rijeka: InTech), 1-21.
40. Lowenstein, P. R. (2009). Crossing the rubicon. Nat. Biotechnol. 27, 42-44. doi: 10.1038/nbt0109-42
41. Maheshri, N., Koerber, J. T., Kaspar, B. K., and Schaffer, D. V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204. doi: 10.1038/nbt1182
42. Marks, W. J. Jr., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172. doi: 10.1016/S1474-4422(10)70254-4
43. Mattar, C. N., Waddington, S. N., Biswas, A., Johana, N., Ng, X. W., Fisk, A. S., et al. (2012). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther. 20, 69-83. doi: 10.1038/gt.2011.216
44. McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., and Fu, H. (2009). Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 16, 1340-1352. doi: 10.1038/gt.2009.85
45. McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., and Samulski, R. J. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112-2118. doi: 10.1038/sj.gt.3302134
46. McLaughlin, S. K., Collis, P., Hermonat, P. L., and Muzyczka, N. (1988). Adeno-associated virus general transduction vectors: analysis of proviral structures.J. Virol.62, 1963-1973.
47. Miller, T. M., Kaspar, B. K., Kops, G. J., Yamanaka, K., Christian, L. J., Gage, F. H., et al. (2005). Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57, 773-776. doi: 10.1002/ana.20453
48. Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., et al. (2013). Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92. doi: 10.1126/scitranslmed.3005795
49. Miyake, N., Miyake, K., Yamamoto, M., Hirai, Y., and Shimada, T. (2011). Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res. 1389, 19-26. doi: 10.1016/j.brainres.2011.03.014
50. Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040-1046. doi: 10.1038/nbt856
51. Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., et al. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10, 615-622. doi: 10.1038/nn1876
52. Ojala, D. S., Amara, D. P., and Schaffer, D. V. (2014). Adeno-associated virus vectors and neurological gene therapy. Neuroscientist. doi: 10.1177/1073858414521870 [Epub ahead of print].
53. Pardridge, W. M. (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 1, 131-139. doi: 10.1038/nrd725
54. Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S. H., Chiodo, V., Pang, J. J., et al. (2008). High-efficiency Transduction of the Mouse Retina by tyrosine-mutant AAV serotype vectors. Mol. Ther. 17, 463-471. doi: 10.1038/mt.2008.269
55. Porras, G., Dehay, B., and Bezard, E. (2014). "Viral vectors in primate research: examples from Parkinson's disease research, " inViral Vector Approaches in Neurobiology and Brain Diseases, ed. R. Brambilla (New York, NY: Humana Press), 331-341. doi: 10.1007/978-1-62703-610-8_17
56. Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19, 1070-1078. doi: 10.1038/mt.2011.22
57. Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.J. Virol. 76, 791-801. doi: 10.1128/JVI.76.2.791-801.2002
58. Rabinowitz, J. E., Xiao, W., and Samulski, R. J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology265, 274-285. doi: 10.1006/viro.1999.0045
59. Rahim, A. A., Wong, A. M., Hoefer, K., Buckley, S. M., Mattar, C. N., Cheng, S. H., et al. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J. 25, 3505-3518. doi: 10.1096/fj.11-182311
60. Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., et al. (2012). Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382-389. doi: 10.1089/hum.2011.200
61. Samulski, R. J., Berns, K. I., Tan, M., and Muzyczka, N. (1982). Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. U.S.A.79, 2077-2081. doi: 10.1073/pnas.79.6.2077
62. Saunders, N. R., Joakim Ek, C., and Dziegielewska, K. M. (2009). The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat. Biotechnol. 27, 804-805. doi: 10.1038/nbt0909-804
63. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., and Asokan, A. (2011). Terminal N-linked galactose is the primary receptor for adeno-associated virus 9.J. Biol. Chem. 286, 13532-13540. doi: 10.1074/jbc.M110.210922
64. Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.N. Engl. J. Med.361, 1651-1661. doi: 10.1056/NEJMoa0901281
65. Spampanato, C., De Leonibus, E., Dama, P., Gargiulo, A., Fraldi, A., Sorrentino, N. C., et al. (2011). Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol. Ther. 19, 860-869. doi: 10.1038/mt.2010.299
66. Tarantal, A. F., and Lee, C. C. I. (2010). Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum. Gene Ther. 21, 143-148. doi: 10.1089/hum.2009.126
67. Taymans, J.-M., Vandenberghe, L. H., Haute, C. V., Thiry, I., Deroose, C. M., Mortelmans, L., et al. (2007). Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18, 195-206. doi: 10.1089/hum.2006.178
68. Towne, C., Pertin, M., Beggah, A. T., Aebischer, P., and Decosterd, I. (2009). Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol. Pain5, 52. doi: 10.1186/1744-8069-5-52
69. Vandenberghe, L. H., Wilson, J. M., and Gao, G. (2008). Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16, 311-319. doi: 10.1038/gt.2008.170
70. Wang, D. B., Dayton, R. D., Henning, P. P., Cain, C. D., Zhao, L. R., Schrott, L. M., et al. (2010). Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol. Ther. 18, 2064-2074. doi: 10.1038/mt.2010.191
71. Weinberg, M. S., Samulski, R. J., and McCown, T. J. (2013). Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology69, 82-88. doi: 10.1016/j.neuropharm.2012.03.004
72. Wolf, D. A., Hanson, L. R., Aronovich, E. L., Nan, Z., Low, W. C., Frey, W. H. II. et al. (2012). Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol. Genet. Metab. 106, 131-134. doi: 10.1016/j.ymgme.2012.02.006
73. Wu, Z., Asokan, A., and Samulski, R. J. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316-327. doi: 10.1016/j.ymthe.2006.05.009
74. Xiao, X., Li, J., and Samulski, R. J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.J. Virol. 72, 2224-2232.
75. Xie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J. H., Su, Q., et al., (2011). MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526-535. doi: 10.1038/mt.2010.279
76. Xu, J., Ma, C., Bass, C., and Terwilliger, E. F. (2005). A combination of mutations enhances the neurotropism of AAV-2. Virology341, 203-214. doi: 10.1016/j.virol.2005.06.051
77. Zhang, H., Xie, J., Xie, Q., Wilson, J. M., and Gao, G. (2009). Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum. Gene Ther. 20, 922-929. doi: 10.1089/hum.2009.125
78. Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440-1448. doi: 10.1038/mt.2011.98
79. Zhang, J., Wu, X., Qin, C., Qi, J., Ma, S., Zhang, H., et al. (2003). A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 14, 365-379. doi: 10.1016/j.nbd.2003.07.005
80. Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., et al., (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A.105, 7827-7832. doi: 10.1073/pnas.0802866105
81. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J. E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080. doi: 10.1038/mt.2008.76